Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DERN study of denosumab in EBV-related nasopharyngeal carcinoma
2017-005017-31Phase 2Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab in nasopharyngeal carcinoma (NPC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Started May 2021; status: completed.
02
Drugs
denosumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2017-005017-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005017-31.